A Phase II Trial Evaluating the Feasibility of Adding Bevacizumab to Standard Osteosarcoma Therapy

Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in pa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Main Authors: Navid, Fariba, Santana, Victor M., Neel, Michael, McCarville, M. Beth, Shulkin, Barry L., Wu, Jianrong, Billups, Catherine A., Mao, Shenghua, Daryani, Vinay M., Stewart, Clinton F., Kunkel, Michelle, Smith, Wendene, Ward, Deborah, Pappo, Alberto S., Bahrami, Armita, Loeb, David M., Willert, Jennifer Reikes, Rao, Bhaskar N., Daw, Najat C.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5812455/
https://ncbi.nlm.nih.gov/pubmed/28631382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30841
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares